| Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer J Cortés, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... New England Journal of Medicine 386 (12), 1143-1154, 2022 | 725 | 2022 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label … SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, ... The Lancet 401 (10371), 105-117, 2023 | 310 | 2023 |
| LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY … J Cortés, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... Annals of Oncology 32, S1287-S1288, 2021 | 140 | 2021 |
| BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—initial results from arm 1, d+ paclitaxel (P), and … P Schmid, SA Im, A Armstrong, YH Park, WP Chung, Z Nowecki, S Lord, ... Journal of Clinical Oncology 39 (15_suppl), 1023-1023, 2021 | 62 | 2021 |
| Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from … S Hurvitz, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... Cancer Research 82 (4_Supplement), GS3-01-GS3-01, 2022 | 60 | 2022 |
| Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: a randomized controlled trial WP Chung, HL Yang, YT Hsu, CH Hung, PY Liu, YW Liu, SH Chan, ... Annals of physical and rehabilitation medicine 65 (2), 101485, 2022 | 31 | 2022 |
| 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY … SA Hurvitz, S Modi, W Li, YH Park, W Chung, SB Kim, J Cortés, ... Annals of Oncology 34, S335-S336, 2023 | 25 | 2023 |
| Health‐related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan HT Ou, WP Chung, PF Su, TH Lin, JY Lin, YC Wen, WT Fang European journal of cancer care 28 (4), e13069, 2019 | 19 | 2019 |
| PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations WP Chung, WL Huang, CH Lee, HP Hsu, WL Huang, YY Liu, WC Su American Journal of Cancer Research 12 (7), 3067, 2022 | 16 | 2022 |
| The prognosis of early-stage breast cancer in extremely young female patients WP Chung, KT Lee, YP Chen, YT Hsu, ZJ Loh, CC Huang, HP Hsu Medicine 100 (1), e24076, 2021 | 7 | 2021 |
| Trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2+ metastatic breast cancer: Results of the randomized phase 3 study DESTINY-Breast03 S Hurvitz, SB Kim, WP Chung San Antonio Breast Cancer Symposium 2021, GS3-01, 2021 | 6 | 2021 |
| Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment WP Chung, HL Song, CL Ho, NT Chiu, WC Su Journal of Clinical Oncology 31 (1), e6-e8, 2013 | 6 | 2013 |
| FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer WP Chung, WL Huang, WA Liao, CH Hung, CW Chiang, CHA Cheung, ... Scientific reports 12 (1), 241, 2022 | 5 | 2022 |
| Abstract PD10-03: BEGONIA: phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): results from Arm 1 D+ paclitaxel … P Schmid, Z Nowecki, SA Im, WP Chung, S Lord, A Armstrong, CX Ma, ... Cancer Research 82 (4_Supplement), PD10-03-PD10-03, 2022 | 4 | 2022 |
| Low expression of cytosolic NOTCH1 predicts poor prognosis of breast cancer patients YL Chen, KT Lee, CY Wang, CH Shen, SC Chen, WP Chung, YT Hsu, ... American journal of cancer research 12 (5), 2084, 2022 | 4 | 2022 |
| ABCB1 Regulates Immune Genes in Breast Cancer HK Chen, YL Chen, CY Wang, WP Chung, JH Fang, MD Lai, HP Hsu Breast Cancer: Targets and Therapy, 801-811, 2023 | 3 | 2023 |
| Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw PA Fu, CY Shen, SR Yang, CH Lee, HW Chen, ECC Lai, WP Chung Scientific reports 13 (1), 8403, 2023 | 3 | 2023 |
| PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 SA Im, B Xu, SB Kim, WP Chung, YH Park, MH Kim, LM Tseng, CF Chung, ... Annals of Oncology 33, S464-S465, 2022 | 3 | 2022 |
| Comparative treatment persistence with bone-targeting agents among asian patients with bone metastases from solid tumors: A multinational retrospective cohort study CY Shen, PCM Au, YH Baek, CL Cheung, WP Chung, JH Kim, ... BioDrugs 36 (3), 381-392, 2022 | 3 | 2022 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial SA Hurvitz, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... ESMO open 9 (5), 102924, 2024 | 2 | 2024 |
